282 research outputs found
Safety and efficacy of formoterol/tiotropium bromide and formoterol/glycopyrronium combination in patients with chronic obstructive pulmonary disease
Background: Chronic obstructive pulmonary disease is characterized by a progressive development of airflow limitation that is not fully reversible. The study investigated the efficacy and safety of formoterol/tiotropium bromide and formoterol/glycopyrronium combination in patients with chronic obstructive pulmonary disease. Glycopyrrolate, a long-acting anti-muscarinic agent is recently approved for the maintenance therapy of chronic obstructive pulmonary disease in combination with formoterol. However, the studies on glycopyrrolate along with long-acting beta 2 agonist, particularly in Indian patients are limited. Hence it was considered worthwhile to determine safety and efficacy of fixed dose combinations of formoterol/ tiotropium vs. formoterol/glycopyrrolate in grade-2 patients of chronic obstructive pulmonary disease patients.
Methods: Efficacy and safety of formoterol/glycopyrrolate and formoterol/tiotropium were compared in Grade-2 patients. Total 68 patients were analysed and the efficacy of treatment was determined by Spirometry, Chronic Obstructive Pulmonary Disease Assessment Test score and Symptom score at day zero (before therapeutic intervention) and at two weeks of interval till 12 weeks.
Results: The treatment with inhaled combination of formoterol/glycopyrrolate and formoterol/tiotropium has shown an improvement in spirometric variable Forced Expiratory Volume (in one second) decrease in mean Symptom score and COPD Assessment Test score among the grade-2 Chronic Obstructive Pulmonary Disease patients.
Conclusions: Combination therapy of formoterol/glycopyrrolate is non-inferior to formoterol/tiotropium in terms of efficacy and safety profile of patients with chronic obstructive pulmonary disease
Recommended from our members
Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies.
BackgroundSmoking is a major risk factor for COPD and may impact the efficacy of COPD treatments; however, a large proportion of COPD patients continue to smoke following diagnosis.MethodsThis post-hoc analysis of pooled data from the replicate 12-week, placebo-controlled GEM1 and GEM2 studies assessed the impact of smoking status on the efficacy and safety of glycopyrrolate 15.6āĪ¼g twice daily vs placebo in patients with moderate-to-severe COPD. Data from 867 patients enrolled in GEM1 and GEM2 were pooled for analysis and grouped by smoking status (57% current smokers, 43% ex-smokers). Forced expiratory volume in 1ās (FEV1) area under the curve from 0 to 12āh, trough FEV1, forced vital capacity, St George's Respiratory Questionnaire (SGRQ) total score, COPD assessment test (CAT) score, transition dyspnea index (TDI) focal score, daily symptom scores, and rescue medication use were assessed in current smokers and ex-smokers. Incidences of adverse events (AEs) and serious AEs (SAEs) were also assessed.ResultsTreatment with glycopyrrolate resulted in significant improvements in all lung function measures, independent of smoking status. In both current and ex-smokers, changes from baseline in trough FEV1 were less marked in patients taking inhaled corticosteroids (ICS) than those not receiving ICS. Changes from baseline in SGRQ total score and rescue medication use were significantly greater with glycopyrrolate compared with placebo, regardless of smoking status. Changes in the CAT score, TDI focal score, and daily symptom scores significantly improved versus placebo, but only in current smokers. Improvements in patient-reported outcomes (PROs) with glycopyrrolate relative to placebo were numerically greater in current smokers than ex-smokers. The incidences of AEs and SAEs were similar regardless of smoking status.ConclusionsIn this post-hoc analysis of GEM1 and GEM2, glycopyrrolate use led to significant improvements in lung function, independent of baseline smoking status; improvements were less marked among patients receiving background ICS, regardless of baseline smoking status. Improvements in PROs were greater with glycopyrrolate than placebo, and the magnitude of changes was numerically greater among current smokers. The safety profile of glycopyrrolate was comparable between current smokers and ex-smokers
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher PD
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3)
AbstractBackgroundChronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the United States. Long-acting muscarinic antagonists (LAMAs) are a class of medications used as maintenance therapy for COPD. The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6Ā Ī¼g twice daily (b.i.d.), compared with an approved long-acting Ī²2-agonist (LABA), indacaterol (IND) 75Ā Ī¼g once daily (q.d.) in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation.MethodsThis 52-week, multicenter, double-blind, parallel-group study randomized patients (1:1) of the United States to receive GLY 15.6Ā Ī¼gĀ b.i.d. or IND 75Ā Ī¼g q.d. both delivered via the NeohalerĀ® device. The primary objective was to assess the safety and tolerability in terms of adverse event (AE) reporting rates over 52 weeks. Safety was also determined by evaluating multiple secondary endpoints, including vital signs, electrocardiograms (ECGs), and time to first moderate or severe exacerbation. Efficacy-related secondary endpoints included pre-dose forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).ResultsOf the 511 randomized patients (GLY, nĀ =Ā 254; IND, nĀ =Ā 257), 81.6% completed the study. The overall incidences of AEs (GLY, 77.3%; IND, 77.0%) and serious AEs (GLY, 13.1%; IND, 13.3%) were comparable between the groups. The incidence of major adverse cardiovascular events was low and comparable between the groups. No clinically relevant differences for vital signs or ECG parameters were observed between the treatment groups. The three sudden deaths reported within 30 days of the treatment (GLY, nĀ =Ā 2; IND, nĀ =Ā 1) were adjudicated as unrelated to the study medication. In terms of efficacy, GLY 15.6Ā Ī¼gĀ b.i.d. showed improvements in pre-dose FEV1 and FVC from baseline, which was comparable to those with IND 75Ā Ī¼g q.d., with no statistically significant differences. No significant differences were observed between the treatment groups in the time to first moderate or severe COPD exacerbation.ConclusionGLY 15.6Ā Ī¼gĀ b.i.d. showed a long-term safety profile comparable to that of IND 75Ā Ī¼g q.d. and provided rapid and sustained bronchodilation over 52 weeks in patients with COPD with moderate-to-severe airflow limitation.Clinical trial registration numberNCT01697696
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD:the value of inhaled corticosteroids
BACKGROUND: For patients with chronic obstructive pulmonary disease (COPD), greater improvements in lung function have been demonstrated for triple versus dual inhaled therapies in traditional spirometry studies. This study was the first to use functional respiratory imaging (FRI), known for increased sensitivity to airway changes versus spirometry, to assess the effect of the inhaled corticosteroid (ICS) component (budesonide) on lung function in patients with moderate-to-severe COPD and a blood eosinophil countā>ā150 cells/mm(3). METHODS: Patients in this Phase IIIb (NCT03836677), randomized, double-blind, crossover study received twice-daily budesonide/glycopyrrolate/formoterol fumarate (BGF) 320/18/9.6Ā Ī¼g fixed-dose triple therapy and glycopyrrolate/formoterol fumarate (GFF) 18/9.6Ā Ī¼g fixed-dose dual therapy over 4Ā weeks, each delivered via a single metered dose Aerosphere inhaler. Primary endpoints were the improvements from baseline for each treatment in specific (i.e. corrected for lobar volume) image-based airway volume (siVaw) and resistance (siRaw) measured via FRI taken at total lung capacity (Day 29). Secondary outcomes included spirometry and body plethysmography. Adverse events were monitored throughout the study. RESULTS: A total of 23 patients were randomized and included in the intent-to-treat analysis (mean age 64.9Ā years, 78.3% males, 43.5% current smokers, mean predicted post-bronchodilator forced expiratory volume in 1Ā s [FEV(1)] 63.6%). BGF and GFF both statistically significantly increased siVaw from baseline at Day 29 (geometric mean ratio [GM], 95% confidence interval [CI]: 1.72 [1.38, 2.13] and 1.53 [1.28, 1.83], respectively, both pā<ā0.0001), with a greater increase observed for BGF versus GFF (GM, 95% CI 1.09 [1.03, 1.16], pā=ā0.0061). Statistically significant reductions in siRaw were also observed with both BGF and GFF (GM, 95% CI 0.50 [0.39, 0.63] and 0.52 [0.40, 0.67], respectively, both pā<ā0.0001). Additionally, significant improvements from baseline in post-dose FEV(1) were observed with BGF and GFF (mean 346Ā mL, pā=ā0.0003 and 273Ā mL, pā=ā0.0004, respectively). Safety findings were consistent with the known profiles of BGF and GFF. CONCLUSIONS: As observed using FRI, triple therapy with BGF resulted in greater increases in airway volume, and reductions in airway resistance versus long-acting muscarinic antagonist/long-acting Ī²(2)-agonist (LAMA/LABA) dual therapy with GFF, reflecting the ICS componentās contribution in patients with moderate-to-severe COPD. Trial registration:Ā ClinicalTrials.gov, NCT03836677. Registered 11 February 2019, https://clinicaltrials.gov/ct2/show/NCT03836677 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-021-01772-2
Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population : Real-World Use and Early Medication Success
We thank Johann Castaneda for his contribution to protocol development, analysis and interpretation of data. Dr Ruth B Murray (Medscript NZ Ltd) provided medical writing assistance under the direction of the authors, funded by AstraZeneca.Peer reviewe
Dual-combination maintenance inhaler preferences in asthma and chronic obstructive pulmonary disease:A patient-centered benefit-risk assessment
Background: A variety of dual-combination maintenance inhalers are used to treat asthma and chronic obstructive pulmonary disease (COPD). Understanding patient preferences for treatment attributes may help select an optimal treatment from the patient perspective. Methods: Patient preferences for maintenance inhaler device and medication attributes were elicited through a discrete choice experiment and used in benefit-risk assessments to calculate predicted choice probabilities (PrCPs) for 14 dual-combination maintenance inhalers in four treatment classes: lower- and higher-dose inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) inhalers for asthma, and ICS/LABA and long-acting muscarinic antagonist (LAMA)/LABA inhalers for COPD. Results: For all treatment classes, reduced exacerbations and faster onset of action were the most important attributes. For all classes, patients were willing to tolerate an extra yearly exacerbation to decrease the medication's onset of action from 30 to 5 min. For patients with asthma using lower-dose ICS/LABA (n = 497), budesonide/formoteml fumarate dihydrate (80 mu g/4.5 mu g) pressurized metered-dose inhaler (pMDI) had the highest PrCP (28.4%), and for those using a higher-dose ICS/LABA (n = 285), PrCPs were highest for mometasone furoate/formoterol fumarate dihydrate (200 mu g/5 mu g) pMDI (27.0%) and budesonide/formoterol fumarate dihydrate (160 mu g/4.5 mu g) pMDI (26.9%). For patients with COPD using an ICS/LABA (n = 574), budesonide/ formoterol fumarate dihydrate (160 mu g/4.5 mu g) pMDI had the highest PrCP (56.6%), and for those using a LAMA/LABA inhaler (n = 217), tiotropium/olodaterol (2.5 mu g/2.5 mu g) soft mist inhaler had the highest PrCP (42.3%). Conclusions: Patient preference data for maintenance inhaler attributes can be used to identify a preference order of inhalers in different treatment classes
- ā¦